10-Q: eXoZymes Q2 Loss Widens Amid Rising Costs, Going Concern Doubt

eXoZymes Inc. reported a significantly widened net loss and increased cash burn for Q2 2025, raising substantial doubt about its ability to continue as a going concern despite new grant awards.

Summary

• eXoZymes Inc., a pre-revenue biotechnology company, reported a net loss of $4,216,707 for the six months ended June 30, 2025, a significant increase from $2,368,988 in the prior year period.
• Cash and cash equivalents decreased by 28.1% to $6,985,858 as of June 30, 2025, from $9,719,310 at December 31, 2024.
• Cash used in operating activities increased to $2,671,532 for the six months ended June 30, 2025, compared to $2,256,599 in the same period last year.
• Total operating costs surged by 92.5% to $4,498,773 for the six months ended June 30, 2025, driven by increases in general and administrative costs (71.3%) and research and development costs (167.6%).
• Management expressed substantial doubt about the company's ability to continue as a going concern due to anticipated funding shortfalls and its pre-revenue status.
• The company was awarded a key industrial partnership with a $3 million share of a $9.2 million U.S. National Science Foundation (NSF) grant.
• An additional grant of $283,805 was received from the National Institute of Health (NIH) BioClick.
• Material weaknesses in internal control over financial reporting were identified, and remediation efforts are ongoing.
• A new wholly owned subsidiary, NCTx LLC, was established on May 5, 2025, to focus on N-trans-caffeoyltyramine development.
• Shareholders approved the 2025 equity incentive plan on July 25, 2025, adding 1,250,000 shares to the pool.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including a widening net loss, increased cash burn, and explicit 'going concern' doubt. Persistent material weaknesses in internal controls add to the risk. While new grants and strategic initiatives are positive, they do not offset the fundamental financial instability and high operational risk for a pre-revenue company.

Positives

• Awarded a key industrial partnership with a $3 million share of a $9.2 million U.S. National Science Foundation (NSF) grant, validating its technology and securing future funding.
• Received an additional $283,805 grant from the National Institute of Health (NIH) BioClick, supporting cell-free high-throughput platform engineering.
• Secured a $1,000,000 cost share grant from the Department of Defense (DOD) BioMADE initiative for cell-free biomanufacturing of isobutanol.
• Established NCTx LLC, a new wholly owned subsidiary, to develop N-trans-caffeoyltyramine, a compound with emerging relevance in metabolic health, gut integrity, and liver function, expanding the product pipeline.
• Development milestones for the exclusive license agreement with The Regents of the University of California have been met, indicating progress in intellectual property utilization.
• Management believes the company has sufficient funds for its currently planned operations in the near term, supported by existing working capital of $6,314,087 and ongoing grant pursuits.

Negatives

• Net loss significantly increased by 78.0% to $4,216,707 for the six months ended June 30, 2025, compared to $2,368,988 in the prior year period.
• Cash and cash equivalents decreased by 28.1% to $6,985,858 as of June 30, 2025, from $9,719,310 at December 31, 2024, indicating substantial cash burn.
• Cash used in operating activities increased to $2,671,532 for the six months ended June 30, 2025, from $2,256,599 in the comparable prior year period.
• Working capital decreased by $3,173,050 to $6,314,087 as of June 30, 2025, reflecting the usage of cash to fund operations.
• The company remains in a pre-revenue stage, with no operating income reported for the periods presented.
• Management explicitly stated 'substantial doubt about its ability to continue as a going concern due to anticipated funding shortfalls and the Company's pre-revenue status'.
• General and administrative costs increased by 71.3% to $3,120,770, and research and development costs increased by 167.6% to $1,378,003 for the six months ended June 30, 2025, indicating rapidly rising expenses.
• Material weaknesses in internal control over financial reporting were identified, and while remediation is ongoing, controls were concluded to be 'not effective at the reasonable assurance level' as of June 30, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to anticipated funding shortfalls and its pre-revenue status, which could lead to inability to meet long-term liabilities.
• The company's ability to meet its long-term liabilities and obligations is dependent on securing additional financial support through continued shareholder funding, raising equity or debt financing, or ultimately achieving profitable operations, with no current arrangements for additional funding.
• There is significant uncertainty associated with the successful development of commercially viable products based on research efforts and patent applications, and technologies may not gain widespread or timely market acceptance.
• Technologies developed by the company may fail to receive necessary regulatory approvals.
• Potential economic recession, tariffs, and other economic changes due to government policy could adversely impact the general business environment, capital markets, and the company's ability to fund operations, obtain equipment, find collaborative partners, and raise capital.
• Changes to United States tariff and import/export regulations may increase the cost of doing business and restrict access to suppliers or customers.
• Government actions to limit research grants and other forms of federal government funding could make it more difficult to find collaborative research partners and directly impact partner companies' and clients' development work.
• Material weaknesses in internal control over financial reporting persist, meaning controls may not prevent or detect all errors and fraud, despite ongoing remediation efforts.

Future Outlook

The company believes it has sufficient funds for its near-term planned operations, supported by current working capital and ongoing efforts to secure additional grants. It intends to continue allocating available capital towards advancing research, development, and commercialization initiatives. If additional capital is required, the company may pursue equity sales, institutional and bank funding, or licensing of intellectual property rights, though no current arrangements for additional funding are in place. Management expects to adjust business and financing plans as economic conditions evolve, particularly in light of potential recessionary periods. Remediation efforts for identified material weaknesses in internal control over financial reporting are ongoing and are expected to materially improve controls.

Management Comments

• "Management believes that eXoZymes's technology is a differentiated and unique synthetic biology platform."
• "Management believes the platform will enable scalable production of chemical molecules found in nature in a process that is alternative to and more environmentally friendly and sustainable than the typical methods used today, such as chemical synthesis, natural extraction, and synthetic biology."
• "eXoZymes believes its technology could significantly change biomanufacturing through leveraging cell-free, multi-step enzyme-based systems that will be able to transform natural or renewable resources into sought after chemicals."
• "The objective with the eXoZymes synthetic biology platform, as it is developed over time, for diverse range of select chemicals will enable the production of pharmaceuticals, fuels, materials, food additives, and novel compounds."
• "Although the Company believes it has sufficient working capital for the near term, management believes that there remains substantial doubt about its ability to continue as a going concern due to anticipated funding shortfalls and the Company's pre-revenue status."
• "The Company's ability to meet its long-term liabilities and obligations depends on securing additional financial support, whether through continued shareholder funding, raising equity or debt financing, or ultimately achieving profitable operations."
• "The Company, with the participation of the Chief Executive Officer and VP of Finance, evaluated... and concluded that, as of June 30, 2025, the disclosure controls and procedures were not effective at the reasonable assurance level."
• "The Company has performed additional analyses, reconciliations, and other post-closing procedures and has concluded that, notwithstanding the material weaknesses in the internal control over financial reporting, the condensed unaudited consolidated financial statements for the periods covered by and included in this Quarterly Report on Form 10-Q fairly state, in all material respects, the financial position, results of operations and cash flows for the periods presented in conformity with GAAP."
• "We expect these changes to materially improve our internal controls."
• "We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened litigation that would have a material adverse effect on our business, operating results, cash flows, or financial condition should such litigation be resolved unfavorably."
• "The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the general economy."
• "The Company continues to monitor changes in tariffs and indirect trade restraints. The Company does not currently expect that supply chain issues will have a significant impact on its business activities."
• "Although unclear at this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn, affect the Company. The Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance become available."

Industry Context

eXoZymes operates in the biotechnology and synthetic biology sector, focusing on developing a cell-free, enzyme-based platform for biomanufacturing. This positions the company within a growing trend towards more sustainable and efficient production of chemicals, pharmaceuticals, and materials. Its receipt of grants from major U.S. government agencies (NSF, NIH, DOD) indicates alignment with national research priorities in advanced biomanufacturing and validates its technological approach. The establishment of a new subsidiary (NCTx LLC) and a joint venture (Neuractas Therapeutics) reflects a common strategy in early-stage biotech to diversify and expand research pipelines, targeting high-value compounds. The pre-revenue status is typical for development-stage companies in this capital-intensive industry, where significant R&D investment precedes commercialization.

Comparison to Industry Standards

• As a pre-revenue biotechnology company, direct financial comparisons to established industry benchmarks are not applicable.
• The company's focus on a 'differentiated and unique synthetic biology platform' leveraging cell-free, multi-step enzyme-based systems aims to provide an alternative to traditional chemical synthesis and natural extraction, suggesting a disruptive approach in the biomanufacturing space.
• The receipt of significant grants from the U.S. National Science Foundation (NSF), National Institutes of Health (NIH), and Department of Defense (DOD) indicates external validation of its research and development efforts, aligning with national strategic interests in advanced biomanufacturing, similar to other innovative biotech startups that secure government funding for foundational research.
• The company's stated goal to produce pharmaceuticals, fuels, materials, food additives, and novel compounds through its platform positions it broadly within the industrial biotechnology sector, where companies like Ginkgo Bioworks or Zymergen (now part of Ginkgo) also leverage synthetic biology for diverse applications, though eXoZymes's specific cell-free approach may offer distinct advantages in scalability and environmental impact if successfully commercialized.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• Not aware of any pending or threatened litigation that would have a material adverse effect on business, operating results, cash flows, or financial condition.
• Expects commercial disputes to arise from time to time in the ordinary course of business.

Related Party Transactions

• As of June 30, 2025, an outstanding receivable of $346 from MDB Capital Holdings, LLC, which is non-interest bearing and expected to be collected in 2025.
• MDB Capital Holdings, LLC, which was a majority owner until the November 2024 IPO, now holds a 48% minority interest as of June 30, 2025.
• Approximately $4,243,022 of the IPO proceeds were used to repay loans from MDB Capital Holdings, LLC shortly after the IPO closing.
• One of the founders of eXoZymes was the head of the laboratory involved in the research and development of patents and associated technology licensed from The Regents of the University of California.

Stakeholder Impact

• **Shareholders**: Face significant risk of further share price depreciation and dilution due to widening losses, substantial cash burn, 'going concern' doubt, and the potential need for future capital raises. The 2025 equity incentive plan also introduces potential dilution.
• **Employees**: Increased compensation expenses and new hires suggest growth in the workforce, but the company's financial instability and 'going concern' doubt could pose risks to job security and long-term benefits if funding is not secured.
• **Customers/Partners**: Continued R&D and new grants could lead to innovative products and stronger collaborations, but the company's financial health and 'going concern' status could raise concerns about its long-term viability as a partner or supplier.
• **Creditors**: The explicit 'going concern' doubt and reliance on future funding sources could increase perceived credit risk and impact the company's ability to secure favorable debt terms.
• **Suppliers**: Increased operating costs indicate higher demand for goods and services, but the company's financial position might lead to scrutiny of payment terms or creditworthiness.

Next Steps

• Secure additional financial support through continued shareholder funding, equity or debt financing, or ultimately achieving profitable operations.
• Continue to allocate available working capital toward advancing research, development, and commercialization initiatives for its synthetic biology platform.
• Pursue additional grants from government agencies and other organizations to improve working capital position.
• Adjust current business and financing plans as more information and guidance become available regarding potential economic recession and government policies.
• Continue ongoing remediation efforts for identified material weaknesses in internal control over financial reporting to improve financial controls.
• Further develop and produce N-trans-caffeoyltyramine through the newly established NCTx LLC subsidiary.
• Continue work with Neuractas Therapeutics on deuterated cannabinoid molecules under the joint venture agreement.

Key Dates

Recommendation

The company is a pre-revenue biotechnology firm with a rapidly increasing net loss and significant cash burn. The explicit disclosure of 'substantial doubt about its ability to continue as a going concern' is a critical red flag, indicating severe financial distress and high risk of insolvency without substantial new funding. While new grants are positive, they are insufficient to offset the fundamental financial instability and the unresolved material weaknesses in internal controls. This filing presents a highly speculative investment with significant downside risk, making it unsuitable for most investors.

Keywords

Biotechnology, Synthetic Biology, Cell-free systems, Biomanufacturing, Pre-revenue, Going Concern, SEC Filing, 10-Q, Research and Development, Grants, N-trans-caffeoyltyramine, Corporate Governance, Financial Reporting, Exozymes